Compare Hims and Hers Health Inc (HIMS) vs MPLX LP (MPLX) Price & Performance

Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.

The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.

MPLX trades at $56.12, down 1.63% with a bearish technical signal. The stock shows strong fundamentals with a 12.33 P/E ratio, 40.45% net income margin, and consistent dividend payments. Recent earnings show mixed results with Q4 2025 beating expectations but subsequent quarters missing targets. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 13.7% upside potential from current levels.

The outlook remains positive given MPLX's resilient midstream business model with fee-based revenues insulating it from energy price volatility. Key risks include potential energy market downturns and execution challenges in the Permian Basin expansion. The company's strong cash flow generation supports its 8% dividend yield, making it attractive for income investors seeking energy exposure with reduced commodity price sensitivity.